Mu Investments Ltd. Lowers stake in Pfizer (PFE)

Pfizer (PFE) : Mu Investments Ltd. reduced its stake in Pfizer by 0.93% during the most recent quarter end. The investment management company now holds a total of 21,280 shares of Pfizer which is valued at $696,069 after selling 200 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Apr 26, 2016.Pfizer makes up approximately 0.44% of Mu Investments Ltd.’s portfolio.

Pfizer opened for trading at $32.56 and hit $33 on the upside on Monday, eventually ending the session at $32.8, with a gain of 0.28% or 0.09 points. The heightened volatility saw the trading volume jump to 3,80,66,813 shares. Company has a market cap of $202,840 M.

Other Hedge Funds, Including , Pggm Investments boosted its stake in PFE in the latest quarter, The investment management firm added 98,463 additional shares and now holds a total of 4,053,675 shares of Pfizer which is valued at $134,865,767. Pfizer makes up approx 0.72% of Pggm Investments’s portfolio.Stokes Hubbell Capital Management boosted its stake in PFE in the latest quarter, The investment management firm added 20,567 additional shares and now holds a total of 42,534 shares of Pfizer which is valued at $1,415,106. Pfizer makes up approx 0.64% of Stokes Hubbell Capital Management’s portfolio.Heritage Investors Management Corp boosted its stake in PFE in the latest quarter, The investment management firm added 4,868 additional shares and now holds a total of 430,925 shares of Pfizer which is valued at $14,005,063. Pfizer makes up approx 1.06% of Heritage Investors Management Corp’s portfolio.Benjamin F. Edwards Company boosted its stake in PFE in the latest quarter, The investment management firm added 645 additional shares and now holds a total of 55,398 shares of Pfizer which is valued at $1,800,435. Pfizer makes up approx 0.37% of Benjamin F. Edwards Company’s portfolio.

On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.

Many Wall Street Analysts have commented on Pfizer. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.